CA3124220A1 - Derives d'oxopyridine substitues - Google Patents
Derives d'oxopyridine substitues Download PDFInfo
- Publication number
- CA3124220A1 CA3124220A1 CA3124220A CA3124220A CA3124220A1 CA 3124220 A1 CA3124220 A1 CA 3124220A1 CA 3124220 A CA3124220 A CA 3124220A CA 3124220 A CA3124220 A CA 3124220A CA 3124220 A1 CA3124220 A1 CA 3124220A1
- Authority
- CA
- Canada
- Prior art keywords
- mmol
- methyl
- mixture
- represents hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
L'invention concerne des dérivés d'oxopyridine substitués et des procédés pour leur préparation, ainsi que leur utilisation pour la préparation de médicaments pour le traitement et/ou la prophylaxie de maladies, en particulier de troubles vasculaires, de préférence de troubles thrombotiques ou thromboemboliques et/ou de complications thrombotiques ou thromboemboliques.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018122825 | 2018-12-21 | ||
CNPCT/CN2018/122825 | 2018-12-21 | ||
PCT/EP2019/085983 WO2020127504A1 (fr) | 2018-12-21 | 2019-12-18 | Dérivés d'oxopyridine substitués |
Publications (1)
Publication Number | Publication Date |
---|---|
CA3124220A1 true CA3124220A1 (fr) | 2020-06-25 |
Family
ID=69143542
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3124220A Pending CA3124220A1 (fr) | 2018-12-21 | 2019-12-18 | Derives d'oxopyridine substitues |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP3898633A1 (fr) |
JP (1) | JP2022514303A (fr) |
KR (1) | KR20210106504A (fr) |
CN (1) | CN113474348A (fr) |
AR (1) | AR117435A1 (fr) |
AU (1) | AU2019407909B2 (fr) |
BR (1) | BR112021009435A2 (fr) |
CA (1) | CA3124220A1 (fr) |
CL (1) | CL2021001613A1 (fr) |
CO (1) | CO2021007908A2 (fr) |
CR (1) | CR20210342A (fr) |
DO (1) | DOP2021000128A (fr) |
EA (1) | EA202191764A1 (fr) |
EC (1) | ECSP21043895A (fr) |
IL (1) | IL283990A (fr) |
JO (1) | JOP20210161A1 (fr) |
MA (1) | MA54521A (fr) |
MX (1) | MX2021007508A (fr) |
PE (1) | PE20211790A1 (fr) |
SG (1) | SG11202104384PA (fr) |
TW (1) | TW202039510A (fr) |
WO (1) | WO2020127504A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3765452B1 (fr) * | 2018-03-15 | 2022-04-13 | Bayer Aktiengesellschaft | Procédé de préparation de deux dérivés de 4-{[(2s)-2-{4-[5-chloro-2-(1h-1,2,3-triazol-1-yl)phényl]-5-méthoxy-2-oxopyridin-1(2h)-yl}butanoyl]amino}-2-fluorobenzamide |
CN114105881B (zh) | 2020-08-31 | 2024-01-26 | 沈阳海诺威医药科技有限公司 | 血小板聚集抑制剂及其制备方法和用途 |
JP2024508970A (ja) | 2021-03-09 | 2024-02-28 | バイエル・アクチエンゲゼルシヤフト | (4s)-24-クロロ-4-エチル-73-フルオロ-35-メトキシ-32,5-ジオキソ-14-(トリフルオロメチル)-32h-6-アザ-3(4,1)-ピリジナ-1(1)-[1,2,3]トリアゾラ-2(1,2),7(1)-ジベンゼナヘプタファン-74-カルボキサミドを含んでいる医薬剤形 |
EP4304714A1 (fr) | 2021-03-09 | 2024-01-17 | Bayer Aktiengesellschaft | Formes cristallines de (4s) -2 4 - chloro-4 - éthyl-7 3 - fluoro-3 5 - méthoxy -3 2,5 - dioxo-1 4 - (trifluorométhyl) -3 2 h -6 - aza-3 (4,1) - pyridina-1 (1) - [ 1,2,3 ] triazola-2 (1,2), 7 (1) -5 dibenzenaheptaphane-7 4 - carboxamide |
WO2022189280A1 (fr) | 2021-03-09 | 2022-09-15 | Bayer Aktiengesellschaft | Solvates de (4s)-24-chloro-4-éthyl-73-fluoro-35-méthoxy-32,5-dioxo-14-(trifluoro-méthyl)-32 h-6- aza-3(4,1)-pyridina-1(1)-[1,2,3]triazola-2(1,2),7(1)-dibenzenaheptaphane-74-carboxamide |
CN114560754A (zh) * | 2022-02-25 | 2022-05-31 | 滁州学院 | 一种烷基醇的制备方法 |
CN116874469B (zh) * | 2023-09-06 | 2023-11-10 | 成都施贝康生物医药科技有限公司 | 一种氧代吡啶类化合物、中间体及其制备方法和用途 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
US8163779B2 (en) | 2006-12-20 | 2012-04-24 | Takeda San Diego, Inc. | Glucokinase activators |
US9809545B2 (en) | 2013-03-27 | 2017-11-07 | Merck Sharp & Dohme Corp. | Factor XIa inhibitors |
TWI633089B (zh) * | 2013-03-28 | 2018-08-21 | 拜耳製藥股份有限公司 | 經取代的酮基吡啶衍生物 |
JP6410819B2 (ja) | 2013-07-23 | 2018-10-24 | バイエル ファーマ アクチエンゲゼルシャフト | 置換オキソピリジン誘導体および第XIa因子/血漿としてのその使用 |
WO2015063093A1 (fr) | 2013-10-30 | 2015-05-07 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substituée |
WO2016046156A1 (fr) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués |
CA2961981A1 (fr) | 2014-09-24 | 2016-03-31 | Bayer Pharma Aktiengesellschaft | Derives d'oxopyridine substitues |
EP3197891B1 (fr) * | 2014-09-24 | 2018-11-21 | Bayer Pharma Aktiengesellschaft | Dérivés de pyridobenzazépine et de pyridobenzazocine inhibant le facteur xia |
EP3197872B1 (fr) | 2014-09-24 | 2019-01-30 | Bayer Pharma Aktiengesellschaft | (2h)-2-oxopyridines en tant qu'inhibiteurs du facteur xia pour le traitement de maladies thrombotiques |
US10077265B2 (en) * | 2014-09-24 | 2018-09-18 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
EP3197880B1 (fr) | 2014-09-24 | 2018-10-24 | Bayer Pharma Aktiengesellschaft | Dérivés d'oxopyridine substitués à effet anti-inflammatoire et anti-thrombotique |
JP2018509426A (ja) * | 2015-03-19 | 2018-04-05 | バイエル ファーマ アクチエンゲゼルシャフト | 血栓症の治療のための因子XIa阻害剤としてのオキソピリジン誘導体 |
JO3703B1 (ar) | 2015-07-09 | 2021-01-31 | Bayer Pharma AG | مشتقات أوكسوبيريدين مستبدلة |
US20180250280A1 (en) | 2015-09-04 | 2018-09-06 | Bayer Pharma Aktiengesellschaft | Substituted oxopyridine derivatives |
-
2019
- 2019-12-18 KR KR1020217022510A patent/KR20210106504A/ko active Search and Examination
- 2019-12-18 MA MA054521A patent/MA54521A/fr unknown
- 2019-12-18 BR BR112021009435-0A patent/BR112021009435A2/pt not_active Application Discontinuation
- 2019-12-18 TW TW108146372A patent/TW202039510A/zh unknown
- 2019-12-18 PE PE2021000903A patent/PE20211790A1/es unknown
- 2019-12-18 EA EA202191764A patent/EA202191764A1/ru unknown
- 2019-12-18 CR CR20210342A patent/CR20210342A/es unknown
- 2019-12-18 SG SG11202104384PA patent/SG11202104384PA/en unknown
- 2019-12-18 AR ARP190103745A patent/AR117435A1/es unknown
- 2019-12-18 JO JOP/2021/0161A patent/JOP20210161A1/ar unknown
- 2019-12-18 CA CA3124220A patent/CA3124220A1/fr active Pending
- 2019-12-18 EP EP19832641.5A patent/EP3898633A1/fr active Pending
- 2019-12-18 CN CN201980091518.1A patent/CN113474348A/zh active Pending
- 2019-12-18 JP JP2021535063A patent/JP2022514303A/ja active Pending
- 2019-12-18 WO PCT/EP2019/085983 patent/WO2020127504A1/fr unknown
- 2019-12-18 MX MX2021007508A patent/MX2021007508A/es unknown
- 2019-12-18 AU AU2019407909A patent/AU2019407909B2/en not_active Ceased
-
2021
- 2021-06-14 IL IL283990A patent/IL283990A/en unknown
- 2021-06-16 EC ECSENADI202143895A patent/ECSP21043895A/es unknown
- 2021-06-16 CO CONC2021/0007908A patent/CO2021007908A2/es unknown
- 2021-06-17 CL CL2021001613A patent/CL2021001613A1/es unknown
- 2021-06-18 DO DO2021000128A patent/DOP2021000128A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210106504A (ko) | 2021-08-30 |
WO2020127504A1 (fr) | 2020-06-25 |
TW202039510A (zh) | 2020-11-01 |
AU2019407909A1 (en) | 2021-05-27 |
SG11202104384PA (en) | 2021-05-28 |
MX2021007508A (es) | 2021-08-05 |
ECSP21043895A (es) | 2021-07-30 |
DOP2021000128A (es) | 2021-09-30 |
EP3898633A1 (fr) | 2021-10-27 |
JP2022514303A (ja) | 2022-02-10 |
PE20211790A1 (es) | 2021-09-09 |
CR20210342A (es) | 2021-08-09 |
MA54521A (fr) | 2022-03-30 |
JOP20210161A1 (ar) | 2023-01-30 |
BR112021009435A2 (pt) | 2021-08-17 |
AU2019407909B2 (en) | 2023-05-25 |
AR117435A1 (es) | 2021-08-04 |
IL283990A (en) | 2021-07-29 |
CL2021001613A1 (es) | 2021-12-03 |
CN113474348A (zh) | 2021-10-01 |
CO2021007908A2 (es) | 2021-07-19 |
EA202191764A1 (ru) | 2021-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2019407909B2 (en) | Substituted oxopyridine derivatives | |
US9765070B2 (en) | Substituted oxopyridine derivatives | |
CN108026072B (zh) | 取代的氧代吡啶衍生物 | |
AU2014242971B2 (en) | Substituted oxopyridine derivatives and use thereof in the treatment of cardiovascular disorders | |
US10138236B2 (en) | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives | |
CN106687458B (zh) | 取代的氧代吡啶衍生物 | |
US10414731B2 (en) | Substituted oxopyridine derivatives | |
US20180250280A1 (en) | Substituted oxopyridine derivatives | |
CA3123324A1 (fr) | Derives d'oxopyridine substitues pour le traitement et/ou la prophylaxie de troubles thrombotiques ou thromboemboliques et/ou de complications thrombotiques ou thromboemboliques | |
CA2979937A1 (fr) | Derives d'oxopyridine comme inhibiteurs du facteur xia pour le traitement de la thrombose | |
US10077265B2 (en) | Substituted oxopyridine derivatives | |
TW201808908A (zh) | 因子XIa抑制劑 | |
JP7546172B2 (ja) | 置換s-アラニナート誘導体 | |
CA3124296A1 (fr) | Derives d'oxopyridine substitues | |
EA044932B1 (ru) | Замещенные оксопиридиновые производные | |
JP2016520111A (ja) | 置換ベンゾキサゾール | |
JP2016520110A (ja) | 置換ベンゾキサゾール | |
JP2008512365A (ja) | 第Xa因子阻害物質として使用する、N−(1−(2,3−ジヒドロ−1H−インデン−5イル)−2−オキソ−3−ピロリジニル)−スルホンアミド誘導体 |